221 related articles for article (PubMed ID: 33753563)
1. IHC versus FISH versus NGS to detect ALK gene rearrangement in NSCLC: all questions answered?
Batra U; Nathany S; Sharma M; Pasricha S; Bansal A; Jain P; Mehta A
J Clin Pathol; 2022 Jun; 75(6):405-409. PubMed ID: 33753563
[TBL] [Abstract][Full Text] [Related]
2. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
[TBL] [Abstract][Full Text] [Related]
4. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
[TBL] [Abstract][Full Text] [Related]
5. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.
Letovanec I; Finn S; Zygoura P; Smyth P; Soltermann A; Bubendorf L; Speel EJ; Marchetti A; Nonaka D; Monkhorst K; Hager H; Martorell M; Sejda A; Cheney R; Hernandez-Losa J; Verbeken E; Weder W; Savic S; Di Lorito A; Navarro A; Felip E; Warth A; Baas P; Meldgaard P; Blackhall F; Dingemans AM; Dienemann H; Dziadziuszko R; Vansteenkiste J; O'Brien C; Geiger T; Sherlock J; Schageman J; Dafni U; Kammler R; Kerr K; Thunnissen E; Stahel R; Peters S;
J Thorac Oncol; 2018 Mar; 13(3):413-425. PubMed ID: 29191776
[TBL] [Abstract][Full Text] [Related]
7. Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.
Ding Y; Sun C; Su W; Miao C; He X; Wang JS; Zhang ZH
Virchows Arch; 2022 Sep; 481(3):405-419. PubMed ID: 35624360
[TBL] [Abstract][Full Text] [Related]
8. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
[TBL] [Abstract][Full Text] [Related]
9. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
[TBL] [Abstract][Full Text] [Related]
10. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M
Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200
[TBL] [Abstract][Full Text] [Related]
12. A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy.
Wang H; Sun L; Sang Y; Yang X; Tian G; Wang Z; Fang J; Sun W; Zhou L; Jia L; Tsao MS; Shi H; Lin D
Lung Cancer; 2019 Apr; 130():135-142. PubMed ID: 30885334
[TBL] [Abstract][Full Text] [Related]
13. Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing.
Wakuda K; Morita M; Sekikawa M; Morikawa N; Miura K; Doshita K; Iida Y; Kodama H; Mamesaya N; Kobayashi H; Ko R; Ono A; Kenmotsu H; Naito T; Murakami H; Muramatsu K; Kawata T; Mori K; Shimizu T; Gon Y; Takahashi T
Int J Clin Oncol; 2024 Feb; 29(2):96-102. PubMed ID: 38183554
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues.
Zhang YG; Jin ML; Li L; Zhao HY; Zeng X; Jiang L; Wei P; Diao XL; Li X; Cao Q; Tian XX
PLoS One; 2013; 8(5):e64821. PubMed ID: 23741400
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.
Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T
Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
Pekar-Zlotin M; Hirsch FR; Soussan-Gutman L; Ilouze M; Dvir A; Boyle T; Wynes M; Miller VA; Lipson D; Palmer GA; Ali SM; Dekel S; Brenner R; Bunn PA; Peled N
Oncologist; 2015 Mar; 20(3):316-22. PubMed ID: 25721120
[TBL] [Abstract][Full Text] [Related]
17. Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC.
Kuang Y; Xu P; Wang J; Zheng Y; Sun X; Li Z; Gan R; Li H; Guo Y; Yao F; Zhu C; Ke Z; Tang K
Mol Diagn Ther; 2021 Jul; 25(4):487-494. PubMed ID: 34133003
[TBL] [Abstract][Full Text] [Related]
18. Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.
Xia P; Zhang L; Li P; Liu E; Li W; Zhang J; Li H; Su X; Jiang G
J Transl Med; 2021 Jul; 19(1):308. PubMed ID: 34271921
[TBL] [Abstract][Full Text] [Related]
19. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.
Thunnissen E; Lissenberg-Witte BI; van den Heuvel MM; Monkhorst K; Skov BG; Sørensen JB; Mellemgaard A; Dingemans AMC; Speel EJM; de Langen AJ; Hashemi SMS; Bahce I; van der Drift MA; Looijen-Salamon MG; Gosney J; Postmus PE; Samii SMS; Duplaquet F; Weynand B; Durando X; Penault-Llorca F; Finn S; Grady AO; Oz B; Akyurek N; Buettner R; Wolf J; Bubendorf L; Duin S; Marondel I; Heukamp LC; Timens W; Schuuring EMD; Pauwels P; Smit EF
Lung Cancer; 2019 Dec; 138():13-18. PubMed ID: 31630043
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?
Kerr KM; López-Ríos F
Ann Oncol; 2016 Sep; 27 Suppl 3():iii16-iii24. PubMed ID: 27573752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]